Impact BioMedical Inc. Announces Pricing of Initial Public Offering
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) — Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new […]
TSX News -
Allied Announces September 2024 Distribution
TORONTO, Sept. 16, 2024 (GLOBE NEWSWIRE) — Allied Properties REIT (“Allied”) (TSX:AP.UN) announced today that the Trustees of Allied have […]
High Income Securities Fund Announces Special Meeting
MILWAUKEE, Sept. 16, 2024 (GLOBE NEWSWIRE) — High Income Securities Fund (the “Fund”) (NYSE: PCF) announced today that a special […]
Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group“) (CSE: PSYG), a life science biotechnology company […]
Stride, Inc. Named Best EdTech Company by Global EdTech Awards
RESTON, Va., Sept. 16, 2024 (GLOBE NEWSWIRE) — Stride, Inc., one of the nation’s leading education companies, has been named […]
Fancamp Welcomes Francis MacDonald to the Board of Directors
VANCOUVER, British Columbia, Sept. 16, 2024 (GLOBE NEWSWIRE) — Fancamp Exploration Ltd. (“Fancamp” or the “Company”) (TSX Venture Exchange: FNC) […]
Fluke Corporation Launches Compact, Versatile iSee Mobile Thermal Camera for Safe and Accurate Electrical Inspection On-the-Go
Everett, Washington, Sept. 16, 2024 (GLOBE NEWSWIRE) — EVERETT, Wash., September 16, 2024 — Fluke Corporation, the market leader in […]
KULR Releases New KULR ONE Space Presentation, CTO to Participate in Upcoming Live Reddit Q&A Discussion
HOUSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a global […]
BIGG Digital Assets Inc. Lists on TSX Venture Exchange
VANCOUVER, British Columbia, Sept. 16, 2024 (GLOBE NEWSWIRE) — BIGG Digital Assets Inc. (“BIGG” or the “Company”)(CSE: BIGG; OTCQX: BBKCF; […]
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
Of the 20 evaluable ovarian cancer patients, there were 5 PRs Of the 43 evaluable ICI-naïve MSS/MSI-L CRC patients without […]
